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Multiple osteochondromatosis (MO), or EXT1/EXT2-CDG, is an autosomal dominant O-linked
glycosylation disorder characterized by the formation of multiple cartilage-capped tumors
(osteochondromas). In contrast, solitary osteochondroma (SO) is a non-hereditary condition. EXT1 and
EXT2, are tumor suppressor genes that encode glycosyltransferases involved in heparan sulfate elongation.
We present the clinical and molecular analysis of 33 unrelated Latin American patients (27 MO and 6 SO).
Sixty-three percent of all MO cases presented severe phenotype and two malignant transformations to
chondrosarcoma (7%). We found the mutant allele in 78% of MO patients. Ten mutations were novel. The
disease-causing mutations remained unknown in 22% of the MO patients and in all SO patients. No second
mutational hit was detected in the DNA of the secondary chondrosarcoma from a patient who carried a
nonsense EXT1 mutation. Neither EXT1 nor EXT2 protein could be detected in this sample. This is the first
Latin American research program on EXT1/EXT2-CDG.
M
ultiple osteochondromatosis (MO; MIM# 133700, 133701), also known as EXT1/EXT2- CDG in the
Congenital Disorder of Glycosylation (CDG) nomenclature1,2 is an autosomal dominant disease. MO is
genetically heterogeneous and 70–90% of patients present mutations in one of two genes: EXT1 (MIM
608177) (8q24.11-q24.13)3 or EXT2 (MIM 608210) (11p12-p11)4,5. Both are ubiquitously expressed tumor-
suppressor genes of the EXT gene family. All members of this gene family have been cloned encode glycosyl-
transferases involved in the adhesion and/or polymerization of heparan sulfate chains (HS)6–10.
Heparan sulfate proteoglycans (HSPG) are ubiquitously expressed at cell surfaces and in extracellular matrices.
They are composed of a core protein and one or more heparan sulfate glycosaminoglycan chains (linear poly-
saccharides formed by alternating N- acetylated or N-sulfated glucosamine units and uronic acid) that interact
with numerous proteins, including growth factors, morphogens and extracellular matrix proteins11. Each HS
binds to a serine unit of a proteoglycan core protein via O-linked-xylosylation binding11,12. The truncated HSPG
disturb specific growth-factor–binding in chondrocytes, resulting in abnormal signaling and altered endochon-
dral ossification, thus leading to MO13.
MO is characterized by the formation of multiple cartilaginous tumors (osteochondromas), that mainly affect
the metaphyses of long bones or the surface of flat bones14–18. Complications may involve bone and surrounding
tissue deformities, fractures or mechanical joint problems, vascular compression, arterial thrombosis, aneurysm,
pseudoaneurysm formation, and venous thrombosis. Pain, acute ischemia, signs of phlebitis or nerve compres-
sion occur alongside the most severe complication, the malignant transformation of osteochondroma to second-
ary peripheral chondrosarcoma (0.5–5% of patients)16–23. EXT1 and EXT2 have been analysed using different
techniques to search for point mutations and structural alterations. Intragenic deletions involving single or
multiple exons of EXT1 or EXT2 genes have been found in about 10% of cases24–29. Additionally, the promoter
of EXT1 was analysed in some cases. The EXT1 core promoter region was reported to map to approximately
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was shown to have a significant effect on EXT1 promoter activity (the
C-allele resulting in a 56% rise in promoter activity) compared to the
G-wild-type allele30. The presence of an additional MO-causing gene
has been proposed to explain the absence of an EXT1 or EXT2 muta-
tion in a small percentage of MO patients (15–30%)17,31,32. To date,
more than 600 different EXT1 and 345 EXT2 mutations have been
found worldwide and an update on all reported mutations is depos-
ited at http://medgen.ua.ac.be/LOVD)20.
This study represents the first Latin American research program in
MO, with a broad spectrum of genomic changes detected, including
10 novel pathogenic mutations identified in EXT1/EXT2-CDG
patients. Twenty-one different mutant alleles in the EXT1 or EXT2
genes were found in a cohort of 27 MO patients, most of them with a
severe phenotype, including two patients with malignant trans-
formation to chondrosarcoma. No mutation was found in six MO
patients after performing sequencing and MLPA analyses.
Results
Phenotypic characterization. We observed multiple osteochon-
dromas in 27 out of 33 patients, who ranged from 3 to 55 years at
diagnosis. Orthopedic deformities of the forearm, shortening of
limbs, ankle, varus or valgus of the knee, short metacarpal bones,
scoliosis, synostosis, arthritis, and vessel or nerve compression were
some common manifestations. The lesions were located in the femur
(71%), tibia (67%), humerus (67%), fibula (62%), radius (52%) and
pelvis (29%), a frequent site of malignant transformation to chon-
drosarcoma. Phenotypic data were available for 78% of the MO
patients (n 5 21), of whom four presented with a moderate pheno-
type (15% of all MO patients) and 17 with a severe presentation of the
disease (63% of all MO patients) (Table 1, Figure 1A). A severe
phenotype ranging from grade IS to IVS was observed in most of
the MO patients (Figure 1B). Seventy six percent of them presented
an age of onset below 5 years and 59% manifested familial inheri-
tance (Table 1). Two patients developed malignant transformation as
a large chondrosarcoma on the pelvis that led to severe vascular and
organ compression: P06, a 32 year-old female with a type IV severe
phenotype, reported by Delgado et al. and P38, a 42 year-old male
with a type IIS severe phenotype (Table 1)22.
Gene sequence and dose analyses of EXT1 and EXT2 exons. Exons
and flanking regions of the EXT1 and EXT2 genes were sequenced
from the genomic DNA of the 33 patients and MLPA analysis was
performed in DNA samples of those with negative results for
sequencing analysis. The mutant allele was found in 78% of the
MO patients including one patient with solitary presentation (P36)
(Table 1). We identified 21 pathogenic mutations, 15 in EXT1 and 6
in EXT2 (five nonsense, six frame-shift, four missense, three splice-
site mutations, and three large deletions identified by MLPA) listed
in Table 2. Six of the EXT1 mutations were novel (p.Val78Glyfs*111,
p.Leu264Pro, p.Lys306*, p.Arg346Thr, c.1164 1 1C . A, and
p.Gln583Arg) as were four of the EXT2 mutant alleles (p.Asp307-
Valfs*45, p.Trp394*, p.Asp539Glnfs*5 and a deletion of exon 4 to
14).
Bioinformatic predictions for the EXT1 missense mutations sug-
gested a pathogenic role for these genomic changes. In particular, the
p.Leu264Pro change was considered ‘‘disease causing’’ by Mutation
Taster (score: 0.999, amino acid sequence changed, protein features
might be affected with potential luminal loss and splice site changes)
and ‘‘probably_damaging’’ by PolyPhen2 (score: 0.997 sensitivity:
0.27; specificity: 0.98), while ESE Finder predicted an increased level
of the enhancer splicing proteins SF2/ASF (score changed from
20.21685 to 1.24048), and SF2/ASF (score changed from 0.4979 to
1.75265). The novel missense mutation, p.Arg346Thr, change from a
basic amino acid (Arg) to a non-polar one (Thr) and it was predicted
to be ‘‘disease causing’’ by Mutation Taster (score 0.999, amino acid
sequence changed, protein features might be affected with potential
luminal loss and splice site changes) and ‘‘probably_damaging’’ by
PolyPhen2 (score: 0.993, sensitivity: 0.47; specificity: 0.96). ESE
Finder predicted diminished levels of enhancer splicing protein
SRSF2 (SC35). The other novel EXT1 missense mutation, p.Gln-
583Arg, is a change from an uncharged polar amionacid (Gln) to a
basic one (Arg) and it was predicted to be ‘‘disease causing’’ by
Mutation Taster (score: 0.999, amino acid sequence changed, protein
features might be affected with potential luminal loss and splice site
changes) although PolyPhen2 predicted it to be ‘‘benign’’ (score:
0.002 sensitivity: 0.99; specificity: 0.30). The Protein Homology
Fold Recognition Engine Phyre2, (http://www.sbg.bio.ic.ac.uk/
phyre2/html, last accessed March 2014) was used to predict the effect
of missense mutations on 3D structure and the missense mutation
p.Arg346Thr removes two fragments of alpha helix between aa 345
and 347, and from aa 635 to 639, and a beta sheet from aa 361 to 368
in EXT1 protein. The p.Leu264Pro mutation adds an alpha helix
structure from aa 161 to 166 and removes an alpha helix from aa
344 to 346, while removing a beta sheet structure from aa 360 to 365
and introducing a segment of beta sheet from aa 724 to 726. The
other novel missense mutation, p.Gln583Arg removes two fragments
of alpha helix between aa 39 and 41, and from aa 635 to 639 in the
EXT1 protein.
In silico analyses for one novel intronic mutation (c.1164 1 1 G .
A) predicted the use of cryptic donor splice sites: Human Splice
Finder (http://www.umd.be/HSF/, last accessed March 2014), con-
sidered the use of a cryptic donor splice site (score: 91.85%) located
74 nucleotides downstream from the wild-type sequence, while
NetGene2 (http://www.cbs.dtu.dk/cgi-bin/webface?jobid5netgene2/
last accessed March 2014) predicted the use of a cryptic donor splic-
ing site (score: 0.76) 201 nucleotides downstream from the wild-type
(score:0.83).
In three patients large deletions were detected by MLPA (Tables 1
and 2). In EXT1 (exon 1, P36) and a deletion of 11 exons (6–16) in
(P12), and the third one was a deletion in EXT2 (exon 6, P04).
Normal MLPA profiles were obtained for 19 patients.
No mutation was found in 12 cases (6 MO and 6 SO) after per-
forming sequencing and MLPA analyses. Most of these patients did
not have a positive family history of osteochondromatosis (Table 1).
Analysis of the EXT1 promoter. We sequenced 435 bp upstream of
the EXT1 gene including the 123-bp region described to contain the
basic promoter elements30 in samples from patients and 9 controls,
but no mutation was detected. We found that four patients (P18, P21,
P34 and P41), and one control individual, were heterozygous carriers
of the C allele of SNP rs34016643, which has been previously shown
to have a significant effect on EXT1 promoter activity, with the C-
allele resulting in a 56% rise in promoter activity compared to the G
(wild–type) allele30. No pathogenic mutation was identified in EXT1
or EXT2 in three of these four patients, while patient P41 bore a
nonsense mutation (c.1219C . T, p.Gln407*) in exon 4 of the
EXT1 gene (Table 1).
Loss of hetereozygosity analysis in a chondrosarcoma. We had
access to a chondrosarcoma sample from P06. We have detected
the heterozygous p.L283* mutation in EXT1 in the tumor sample.
We further analysed both genes by MLPA and we did not detect
any dose alteration in the chondrosarcoma from this patient. The
patient was heterozygous for the single nucleotide polymorphism
rs11546829 in exon 3 of the EXT1 gene. Loss of heterozygosity for
this marker was not observed in the analysis of DNA in the tumor
tissue.
Discussion
This work represents the first clinical, biochemical and molecular
research on multiple hereditary osteochondromatosis (EXT1/EXT2-
CDG) in Latin American patients. Thirty-three unrelated patients
www.nature.com/scientificreports
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were studied, 27 of which presented with MO. The mutant allele was
identified in 21 of these patients (78%). EXT1 mutations (71%) were
more common than EXT2 mutations (29%) and most of the EXT1
mutations were located in the first six exons. These results are con-
sistent with recent studies reporting that EXT1 is responsible for
,65–75% of MO cases20,27.
The 67% of EXT1 mutations (10/15), were located in exon 1 or 2,
which encode the exostosin domain of the EXT1 protein (from
amino acid 111 to 396). Most of these patients presented a severe
phenotype (67%). Twenty per cent of EXT1 mutations (n 5 3) were
located in the glycosyltransferase domain (from amino acid 480 to
729) (Table 2). In contrast, EXT2 mutations (n 5 6) were more
frequent in the last exons. Thirty three per cent of the EXT2 muta-
tions (n 5 2) were found in the exons that encode the glycosyltrans-
ferase domain (from exon 10 to 14) (Table 2). The structure of the
different EXT1 and EXT2 protein domains was analyzed using
Phyre2 to predict a decrease or loss of protein function according
to the detected mutations and the altered structure of protein
Figure 1 | Genotype–phenotype association in MO patients (n 5 27). (A) Graph showing the proportion of severe phenotype (blue), mild phenotype
(red) and patients with phenotype not available (green) and the distribution of EXT1 and EXT2 mutations or no mutations identified (NM) within each
category. (B) Grade of phenotype severity among severely affected patients and distribution of EXT1 and EXT2 mutations or no mutations identified
(NM) within each category.
Table 2 | List of mutations in EXT1 or EXT2 gene in MO patients
Gene Patient Exon-Intron DNA Deduced protein change Mutation Type Publication
EXT1 P37 Ex 1 c.248_249insA, p.Gln84Alafs*105 Frameshift Francannet, et al 2001
EXT1 P15 Ex 1 c.232dupG p.Val78Glyfs*111 Frameshift This study
EXT1 P14 Ex 1 c.369_370delAG p.Lys126Asnfs*62 Frameshift Ciavarella, et al, 2013
EXT1 P05 Ex 1 c.752delT p.Leu251* Nonsense Ciavarella, et al, 2013
EXT1 P17 Ex 1 c.791T . C p.Leu264Pro Missense This study
EXT1 P061 Ex 1 c.848T . A p.Leu283* Nonsense Delgado, et al, 2012
EXT1 P16 Ex 1 c.916A . T p.Lys306* Nonsense This study
EXT1 P36 Ex1 ex1del Unknown Deletion LOVD
EXT1 P40 Ex 2 c.1018C . T p.Arg340Cys Missense Philippe, et al, 1997
EXT1 P08 Ex 2 c.1037G . C p.Arg346Thr Missense This study
EXT1 P28 In 3-4 c.1164 1 1G . A - - Splice site This study
EXT1 P41 Ex 4 c.1219C . T p.Gln407* Nonsense LOVD
EXT1 P02 Ex 6 c.1469delT p.Leu490Argfs*9 Frameshift Anh, 1995
EXT1 P29 In 8-9 c. 1722 1 1G . A - - Splice site Jennes I et al, 2008
EXT1 P25 Ex 9 c.1748A . G p.Gln583Arg This study
EXT2 P19 In 3-4 c.626 1 1G . A - - Splice site Vink et al. 2004
EXT2 P13 Ex 5 c.920_929del10insTG p.Asp307Valfs*45 Frameshift This study
EXT2 P04 Ex 6 ex6del Unknown Deletion Leube, et al, 2008
EXT2 P01 Ex 8 c.1182G . A p.Trp394* Nonsense This study
EXT2 P27 Ex 10 c.1616_1623del8ins10 p.Asp539Glnfs*5 Frameshift This study
EXT2 P12 Ex 4-14 ex4-14del Unknown Deletion This study
Novel mutations are indicated in bold. We considered as new mutations those not published and/or not mentioned in the LOVD databases. LOVD:http://medgen.ua.ac.be/LOVDv.2.0/
1Patient with malignant transformation to chondrosarcoma.
www.nature.com/scientificreports
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domains32 (Protein Homology Fold Recognition Engine, http://
www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi?id5index). Regarding
the 3-D prediction for two novel EXT1 missense mutations, p.Leu-
264Pro and p.Arg346Thr, the Phyre2 bioinformatic tool showed that
both mutations produce impairment in protein folding or alterations
in the exostosin or glycosyltransferase domains. For the third one,
p.Gln583Arg, Phyre2 showed the removal of alpha helix structures
with possible alterations in EXT1 glycosyltransferase domain. A type
II severe phenotype (IIS) was found in patients carrying the two first
missense mutations (P17 and P08), and a severe phenotype (IIIS) was
observed in P25 carrying the p.Gln583Arg mutation.
Six out of the 14 mutations in the EXT1 gene (p.Val78Glyfs*111,
p.Leu264Pro, p.Lys306*, p.Arg346Thr, c.1164 1 1C . A and
p.Gln583Arg) and four of the six EXT2 mutant alleles (p.Asp-
307Valfs*45, p.Trp394*, p.Asp539Glnfs*5, and exon4-14del) were
novel. Although some mutation hotspots have been reported20
(http://medgen.ua.ac.be/LOVDv.2.0/), we did not observe recurrent
EXT1 or EXT2 mutations in patients in this study. The missense
mutation c.1018C . T (p.Arg340Cys) observed in P40 and the
exon 6 deletion c.1469delT (p.Leu490Argfs*9) found in P02 were
previously described to cause the impairment of heparan sulfate
synthesis20,33.
The MLPA analysis in gDNA of patient P36, showed the complete
deletion of EXT1 exon 1. This patient had previously been reported as
an SO case because he only had one lesion, but this detection in
germline DNA allow us to change the diagnosis into MO patient
with very mild symptoms (only a single osteochondroma lesion)33
(Table 1 and 2). Two molecular defects in EXT2 were detected by
MLPA: the deletion of exon 6 (P04) and of 10 exons (from exon 4 to
exon 14) in patient P12. This patient also carried an abnormal karyo-
type (an 18 q deletion).
Splice-site mutations were detected in EXT1 in two patients. One
of them, c.1164 1 1G . A in intron 3, was a novel mutation observed
in patient P28. This novel mutation was analyzed in silico and the use
of alternative cryptic donor sites was predicted. The phenotype in
these patients was severe, presenting deformity of the limbs, valgus,
restricted joint movement and scoliosis. Furthermore, one splice site
mutation previously described was detected in P19 in EXT2. Clinical
data were not available for this patient25, There are several possible
explanations for the lack of identification of mutations in some of the
MO patients (22%). The mutation may have been in the EXT1 or
EXT2 genes but in regions that were not analyzed. We did not look
for mutations in deep intronic regions or in the 59 and 39 UTR
sequences. Instead, the promoter region was genotyped and no
mutation was detected. A recent study described a regulatory role
for a G/C SNP (rs3401643) located at position 21158 bp, within a
USF1 transcription factor binding site30. These authors observed that
the presence of the C-allele resulted in a ,56% increase in EXT1
promoter activity. The effect of this allele in the four patients of the
present study who are heterozygous for it will require further studies.
It is well established that methylation of cytosine residues in the
promoter region leads to transcription repression in tumor sup-
pressor genes; nevertheless this does not seem to be the case for
EXT1 and EXT2 promoters in osteochondromas or in chondrosar-
comas34,35. Finally, the possible existence of other genes responsible
for MO should also be considered. A putative EXT3 gene, located on
the short arm of chromosome 19, has been proposed to explain the
absence of an EXT1 or EXT2 mutation in a small percentage of MO
patients (15–30%). Nevertheless, the existence of this third locus is
generally accepted to be a false linkage result.
Inactivating mutations in the EXT1 and EXT2 genes were prev-
iously reported as the most common event in MO patients resulting
in the formation of non-functional EXT1 or EXT2 proteins with a
variable degree of expression in tissues27,36. We observed 11 truncat-
ing mutations that create premature stop codons presenting a high
grade of severity in patient’s phenotype (Table 1 and 2). One of these
patients (P06) presented malignant transformation to chondrosar-
coma and we detected the p.Leu283* mutation in the EXT1 gene.
Very low or null levels of EXT1 and EXT2 proteins were detected by
Western blot in this patient. However, in these experiments, the
bands corresponding to GAPDH (control protein) were very weak
and the lack of additional sample precluded repetition. We think that
in spite of the technical problems, this observation should be
reported to allow comparisons with other studies. Obviously, further
cases should be analyzed to confirm these findings. The loss of EXT2
protein suggests that EXT1 mutations probably interfere with the
function of exostosin’s complexes in the Golgi, inactivating the
holoenzyme, degrading the whole protein, or interfering in some
other function in the Golgi37.
Several studies have suggested that MO patients present a more
severe phenotype due to EXT1 mutations than EXT2 mutations16,18,21
while other studies could not confirm this observation23,36. Pedrini
et al 2011 recently performed a genotype–phenotype association
study in a large cohort of MO patients and identified some specific
correlation according to a new clinical classification system31. Our
patients presented some of the most common manifestations,
including orthopedic deformities of the forearm, ankle, varus or
valgus of the knee, arthritis, vessels and nerve compression and very
short stature (below the third percentile). The bones most often
affected were tibia, femur, radius, humerus and fibula. Never-
theless, we observed a severe phenotype (12% type IS, 53% type
IIS, 12% type IIIS and 23% type IVS) in 63% of MO patients
(Figure 1). The remaining 15% presented with a moderate phenotype
without a family history of the disease. We observed that the grade of
severity differed between the proband and other affected members in
the family, according to previously reported intra-familial variabil-
ity18,38. Nevertheless, no family history for MO was reported in 56%
of MO patients. Patients with a mutation in the EXT2 gene showed a
smaller number of affected bones (data not shown) consistent with a
recent study39. The most frequently observed skeletal deformations
in our patients were shortening of limbs, varus or valgus knee, short
metacarpal bones, scoliosis, shortened stature and synostosis, with
no evidence of differences between the grade of severity in the
phenotype observed in patients with EXT1 or EXT2 (Figure 1).
Genotype–phenotype correlations are difficult to establish in MO
patients because most of the EXT1 and EXT2 variants are private
mutations20.
Malignant transformation to a chondrosarcoma is the most
important complication in MO, and has been estimated to occur in
0.5–5% of patients17. Patients P06 and P38 developed malignant
tumors, which gives a frequency of malignant transformation of
7% in our cohort of patients. Patient P06 bore the pathogenic muta-
tion c.848T . A (p.Leu283*) in the first exon of the EXT1 gene22,
while no mutation was detected in P38, neither in EXT1 nor EXT2
(Table 1). It has been shown that hereditary osteochondromas and
secondary chondrosarcomas are associated with a second mutational
hit in the EXT genes40,41. We thus investigated this possibility in DNA
extracted from the osteochondroma tissue resected from P06 by
Sanger sequence and MLPA but we found no evidence of a somatic
mutation as a second hit in any of these genes. The presence of
genetic rearrangements at the EXT1 and EXT2 loci (as the second
mutational hit) in P06 osteochondromas and secondary chondrosar-
comas was ruled out.
In conclusion, we have identified the disease-causing mutation in
21 out of 27 MO patients, including 10 mutations described for the
first time. No mutation was identified in SO cases. Structural analyses
predicted a disruption of important domains of EXT1 proteins bear-
ing missense mutations. A potentially functional promoter poly-
morphism was found in three patients with no other mutation, in
one patient with a disease-causing mutation and in one control. No
second hit was identified in a sample from a chondrosarcoma.
Further studies are needed to identify the molecular bases of the
www.nature.com/scientificreports
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disease in 22% of the patients of this cohort and to understand the
mechanisms underlying the malignant transformation process.
Methods
Patients and control individuals. We investigated 33 patients (18 males and 15
females), from unrelated pedigrees with osteochondromatosis from Chile and
Argentina (27 MO and 6 SO). Nine control samples from healthy subjects were
included in the promoter studies. Diagnosis was made on the basis of clinical
manifestations and confirmed by physical and/or radiographic examinations at the
Orthopedic and Imaging Departments, Children’s Hospital of Córdoba, National
University of Córdoba, Argentina. DNA and tissues samples from patients and their
relatives were obtained together with their informed consent in accordance with the
Helsinki Declaration as revised in 2000. The study was approved by the Ethics
Committee (CIEIS) Act Nu 95/2007. Genomic DNA was obtained from peripheral
blood leukocytes and tissue samples from discarded tissues obtained by surgery, using
the Wizard Genomic DNA purification Kit (Promega, Madison, WI). DNA was
extracted according to the manufacturer’s instructions.
Clinical studies and phenotypic data. Clinical variables were analyzed according to a
scale established by the Musculoskeletal Tumoral Society with some modifications18.
This scale includes the evaluation of all palpable lesions, patient’s height, deformities,
and functional limitations. Lesion quality and the severity of the disease were assessed
according to age of onset (before/after 3 years), number of exostoses (more/less than
10 osteochondromas), vertebral location of the exostoses (absence or presence),
stature (above/below 10th percentile), and functional rating (good or fair). The degree
of severity was classified as mild (M) or severe (S). Four subcategories were defined in
patients with a severe phenotype (from types IS to IVS)16,18.
Genotyping and mutation analysis. The 11 EXT1 and 13 EXT2 coding exons and
their intronic flanking regions were amplified by PCR from genomic DNA. Primer
sequences and PCR conditions were as described by Sarrión et al 201342. All
fragments, except those corresponding to exon 1 of EXT1, could be amplified by PCR
simultaneously. Exon 1 of EXT1 and exon 2 of EXT2 were split into several
overlapping fragments, to obtain amplification products that did not exceed 650 bp.
PCR was performed in a 50-ml reaction volume, containing ,100 ng of genomic
DNA, 1–2 mM MgCl2, 0.2 mM of each dNTP, 0.4 mM of each forward and reverse
primer and 0.7 U of GoTaqR Flexi polymerase (Promega, Madison, WI). All PCR
programs included an initial denaturation of 4 min at 95uC, followed by 35 cycles of
30 sec at 95uC, 30 sec at annealing temperature (Ta) and 1 min at 72uC. An extension
at 72uC was then performed for 5 min. The annealing temperature was 60uC for all
primer combinations, except during the amplification of overlapping regions of exon
1 of EXT1. For these primer combinations, Ta was set at 55uC for ex1.1 and 57uC for
ex1.2 and ex1.3. The EXT1 promoter region, between positions 21285 and 2851, was
also analyzed by sequencing. The PCR reaction was performed as described above
with a Ta of 55uC. All PCR products were purified using a PCR purification kit (GE
Healthcare) and sequenced with BigDye 3.1 (Applied Biosystems Life Technologies).
The sequences were analyzed in an ABI PRISM 3730 DNA Analyzer (Applied
Biosystems Life Technologies).
The presence of all detected mutations was confirmed by digestion with the
appropriate restriction enzyme. Novel mutations were confirmed by analyzing 100
control alleles. The mutations were given the official HGVS nomenclature (www.
hgvs.org). The reference sequences were NM_000127.2 for EXT1 and NM_000401.3
for EXT2.
MLPA. The number of copies of the EXT1 and EXT2 exons present in the patient’s
genomic DNA was analyzed using the multiplex ligation-dependent probe
amplification (MLPA) technique designed by MRC-Holland (code #P215-B1 EXT,
MRC-Holland, Amsterdam, The Netherlands) following the manufacturer’s
instructions. PCR products were run on an ABI 3730 DNA Analyzer capillary
sequencer (Applied Biosystems, Forster City, CA, USA). Peaks were analyzed using
Coffalyser v9.4 software (MRC-Holland Vs 05; 30-08-2007). The proportion of each
peak relative to the height of all peaks was calculated for each sample and then
compared to proportions for the corresponding peak averaged for a set of at least ten
normal DNA samples. Samples with ratios between 0.7 and 1.3 were considered as
bearing a normal copy number. Ratios below 0.7 were considered to correspond to
deletions, and above 1.3 to duplications. Each positive result was confirmed in a
second independent MLPA reaction.
Assessment of functionality of missense mutations. In order to assess the possible
pathogenic effect of the new missense mutations, the changes were analyzed using
three in-silico online tools: PolyPhen-2 (Polymorphism Phenotyping v2; http://
genetics.bwh.harvard.edu/pph2/, last accessed March 2014), Mutation Taster (http://
www.mutationtaster.org/, last accessed March 2014, and ESE Finder 3.0 (ESE: Exonic
Splicing Enhancer; http://rulai.cshl.edu/cgi-bin/tools/ESE3/esefinder.
cgi?process5home, last accessed March 2014). Protein Homology Fold Recognition
Engine (http://www.sbg.bio.ic.ac.uk/phyre2/html, last accessed March 2014) was
used to predict the implications of missense mutations for EXT1 3D structure Human
Splice Finder (http://www.umd.be/HSF/, last accessed March 2014) and NetGene2
(http://www.cbs.dtu.dk/cgi-bin/webface?jobid5netgene2, last accessed March 2014)
online tools were used to assess the possible effect of novel intronic mutations on
splicing.
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